Interviews

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

Christopher Depner, PhD, assistant professor of health and kinesiology, University of Utah, speaks to the current reliability of wearable sleep devices to impact health outcomes, privacy concerns, and more.

Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, discusses the recent FDA approval of deuruxolitinib for the treatment of moderate to severe alopecia areata.

In part 1 of this interview, Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), explained the research she presented at the 25th International AIDS Conference and the disparities migrant workers continue to encounter in HIV care.

Accessia Health works with advocacy groups to understand specific needs, such as travel assistance, affordable care, and diagnostic testing, ensuring a personalized and human-centered approach to health equity.

Aravindhan Veerapandiyan, MD, of the Division of Pediatric Neurology at the University of Arkansas for Medical Sciences, discussed the Duchenne muscular dystrophy (DMD) therapy landscape and barriers to treatment access.

We spoke with Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), who advocates at regional and global levels for policy reform of discriminatory practices that put migrant workers at risk of HIV and AIDS.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, considers dupilumab the "gold standard" for itch control in patients with atopic dermatitis due to its minimal adverse effects.

Martha Gulati, MD, MS, discusses the accomplishments of the American Society of Preventive Cardiology (ASPC) during her presidency and emphasizes the importance of advancing preventive cardiology.

“We are at an inflection point regarding treatment of obesity,” said Robert Kushner, MD, MS, Northwestern University Feinberg School of Medicine.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast.

This research presented at AIDS 2024 shows that cognitive behavioral therapy (CBT) groups help to fill an unmet need among older persons living with HIV: to overcome the age-related health disparities this group experiences from being in long-term care and improve their health outcomes.

A Q&A With Maria Lopes, MD, MS

In advance of this year’s American Society for Preventive Cardiology (ASPC) 2024 Congress on CVD Prevention, we spoke with ASPC President-Elect Michael Shapiro, DO, FASPC, about the many can't-miss sessions at this year's record-breaking event.

Those in minority groups face barriers even after they’ve made the hard decision to seek mental health care. The Department of Labor aims to address systemic issues on a personal level.

Mina Massaro-Giordano, MD, discusses how raising awareness about dry eye can help patients avoid worsening the condition.

On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.

Patricia Cioe, PhD, presented data at AIDS 2024 from a study that investigated the impact of peer support on people living with HIV who smoke, a group for whom there are higher rates of cardiac events and cancer.

Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses possible federal policies to help mitigate ongoing and future cancer drug shortages.

Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses different policy approaches to address the ongoing cancer drug shortage.

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory (R/R) follicular lymphoma.

Health care inequity is costing the United States billions of dollars without providing quality outcomes for patients with rare and chronic diseases, Tiara Green, MSEd, president of Accessia Health, tells The American Journal of Managed Care.

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research on equity challenges within health technology assessment.

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, discusses current and future uses in digital health care.

For Minority Mental Health Awareness Month, the Employee Benefits Security Agency (EBSA) in the US Department of Labor highlights the critical need to address mental health disparities among racial and ethnic minorities.

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).